News
  Date Title View
Apr 7, 2017
BURLINGTON, Mass., April 07, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Yamo Deniz, MD, has been named Chief Medical Officer (CMO). This appointment strengthens the company's leadership with an industry veteran who brings extensive experience leading medical and clinical development te...
Apr 4, 2017
BURLINGTON, Mass., April 04, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the U.S. Patent and Trademark Office has issued two new patents covering the company's lead investigational product candidate ZilrettaTM (FX006). The new patents further strengthen the existing patent estate ...
Mar 28, 2017
BURLINGTON, Mass., March 28, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at Needham & Company's 16th Annual Healthcare Conference on Tuesday, April 4, 2017 at 3:40 p.m. EDT at the Westin Grand Central Hotel in New ...
Mar 9, 2017
NDA for ZilrettaTM (FX006) filed in December 2016 and accepted by FDA in February 2017PDUFA action date set for October 6, 2017Commercialization plans on target for potential Q4 launch of ZilrettaFrederick Driscoll, Chief Financial Officer, to retire eff...
Mar 3, 2017
BURLINGTON, Mass., March 03, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at two upcoming investor conferences: Raymond James 38th Annual Institutional Investors Conference...
Mar 2, 2017
BURLINGTON, Mass., March 02, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to provide an update on business operations and report its fiscal year 2016 financial results on Thursday, March 9, 2017, at 4:30 p.m. ET. The dial-in number...
Feb 23, 2017
BURLINGTON, Mass., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported it has enrolled the first patient in a clinical trial to evaluate the safety of repeat administration of its investigational drug candidate Zilretta (also known as FX006) in patients with osteoarthritis (OA) of the knee. Th...
Feb 15, 2017
BURLINGTON, Mass., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the RBC Capital Markets Global Healthcare Conference on Wednesday, February 22, 2017 at 8:30 a.m. Easte...
Feb 7, 2017
FDA Reviewing Zilretta as Potential New Treatment for Osteoarthritis of the Knee Assigns PDUFA date of October 6, 2017 BURLINGTON, Mass., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (...
Dec 12, 2016
BURLINGTON, Mass., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced it has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead investigational product candidate Zilretta (also known as FX006), which is being evaluated to treat patients with ...
FirstPrevious
2
... NextLast
= add release to Briefcase